EMG
ONCT

Ellington Management Group’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Ellington Management Group’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-130
Closed -$323K – 923
2018
Q1 		$323K Buy
+130
New +$290K 0.02% 564

Other funds holding ONCT

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Ellington Management Group's ONCT Position: Q2 2018 in Review

Ellington Management Group sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q2 2018, closing a stake of 130 shares — an estimated $323K sold.

Ellington Management Group first reported a position in ONCT in Q1 2018 and held it in 1 quarter. The position peaked at $323K in Q1 2018. 55 funds tracked by Wall St. Rank hold ONCT as of Q2 2018.

  • Ellington Management Group reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
  • Ellington Management Group sold 130 Oncternal Therapeutics, Inc. Common Stock shares in Q2 2018, an estimated $323K.
  • Ellington Management Group first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q1 2018 and held it in 1 quarter.
  • Ellington Management Group's Oncternal Therapeutics, Inc. Common Stock position peaked at $323K in Q1 2018.
  • 55 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q2 2018.

Based on Ellington Management Group's 13F filing for Q2 2018, filed 14 Aug 2018.